Indivior

Overview

Indivior PLC is a global pharmaceutical company dedicated to treating opioid use disorder (OUD) and related conditions. Established in December 2014 as a spin-off from Reckitt Benckiser Group PLC, it is publicly traded on the London Stock Exchange. The company aims to address the opioid crisis by providing access to evidence-based treatments that can significantly improve the lives of those affected.

Core products include Suboxone, a combination of buprenorphine and naloxone, Sublocade, a monthly injectable formulation, and Opvee, a naloxone product for emergency overdose response. Indivior is also developing INDV-6001, a long-acting injectable. The company engages with healthcare providers, government agencies, and patient advocacy groups to promote awareness and education about addiction as a chronic disease.

Basic Information

Contact Details

• Phone: +1 804-379-1090
• Website: indivior.com
• LinkedIn: linkedin.com/company/indivior

Key Focus Areas & Initiatives

• Opioid use disorder & rescue medications
• Biotechnology: pharmaceutical preparations
• Health care
• Pharmaceutical manufacturing
• Global healthcare
• Naloxone
• Drug regulation
• Addiction recovery science
• Pharmaceutical innovation
• Medical treatment
• R&D investment
• Drug patents
• Treatment adherence
• Pharmaceutical development
• Sublocade
• Healthcare providers
• Comprehensive addiction care
• Recovery care
• Medication compliance
• Medications for addiction
• Healthcare innovation
• Opioid dependence
• Generic competition
• Health policy
• Mental health
• Opioid addiction
• Opioid treatment access
• Global market
• Medication safety
• Injectable buprenorphine
• Mental health services
• Suboxone
• Addiction stigma reduction
• Evidence-based medicine
• Opioid epidemic response
• Healthcare access
• Medical and diagnostic laboratories
• Treatment innovation
• Financial reporting
• Recovery support
• Addiction science
• Addiction therapy
• Public health emergency
• Pharmacotherapy
• Healthcare advocacy
• Mental health treatment
• Opioid overdose treatment
• Opioid dependence management
• Opioid crisis
• Addiction treatment
• Medication-assisted treatment
• Drug development
• Patient outcomes
• Biopharmaceutical
• Long-acting buprenorphine
• Clinical research
• Substance use disorder therapies
• Data analytics
• Medical therapies
• Medical research
• Substance use disorder
• Extended release injection
• Patient safety
• Therapeutic areas
• Fentanyl
• Drug approval
• Patient-centered care
• Long-acting injectable
• Opioid overdose
• Corporate governance
• Ethical compliance
• Biopharmaceuticals
• Community engagement
• Responsibility initiatives
• Patient monitoring
• Regulatory affairs
• Corporate integrity
• Pipeline management
• Substance use prevention
• Mental illness treatment
• Research and development
• Sustainability in healthcare
• Transparency program
• Health system partnerships
• Corporate collaborations
• Stakeholder engagement
• Investor relations
• Social responsibility
• Global health initiatives
• Patient education
• Integrity and compliance
• B2B
• Manufacturing
• Distribution
• Health, wellness & fitness
• Medical
• Hospital & health care
• Medical & diagnostic laboratories
• Medical practice
• Mechanical or industrial engineering

Technologies Used

• CSC Corporate Domains
• Google Tag Manager
• Microsoft Office 365
• Mobile Friendly
• Outlook
• Rackspace MailGun
• React
• Remote
• Salesforce
• Typekit
• Workday Recruit

Affiliated Organizations & Regional Branches

• Opiant Pharmaceuticals
• Rhode Island Suboxone Doctors